Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Fabian Schmidt; Yiska Weisblum; Frauke Muecksch; Hans-Heinrich Hoffmann; Eleftherios Michailidis; Julio C. C. Lorenzi; Pilar Mendoza; Magdalena Rutkowska; Eva Bednarski; Christian Gaebler; Marianna Agudelo; Alice Cho; Zijun Wang; Anna Gazumyan; Melissa Cipolla; Marina Caskey; Davide F. Robbiani; Michel C. Nussenzweig; Charles M. Rice; Theodora Hatziioannou; Paul D Bieniasz.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-140871

Documentos relacionados

  1. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
  2. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
  3. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike.
  4. Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children.
  5. Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout.
  6. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.
  7. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
  8. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
  9. Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV.
  10. SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity.